Urokinase, a human plasminogen activator, is used clinically to promote the dissolution of thrombi.
尿激酶是一种纤溶酶原激活剂，临床上用于治疗血栓。
The thrombolytic effect was compared between urokinase (UK) and human tissue plasminogen activator (t-PA) in rabbits with experimental iliofemoral artery thrombus.
本文用尿激酶(UK)和人体组织型纤溶酶原激活剂(t - PA)进行了兔髂股动脉血栓实验性溶解的对照研究。
Objective: To identify the significance of urokinase-type plasminogen activator expression in patients with epithelial ovarian carcinoma.
目的：探讨尿激酶型纤溶酶原激活因子的蛋白表达与上皮性卵巢癌生物学行为的关系。
According to reports, Nattokinase has plasmin-like bio-characteristic that lyses fibrin directly, or increases activity of pro-urokinase and t-PA (Tissue Plasminogen Activator).
据报道，纳豆激酶有和胞浆素一样的可直接分解纤维蛋白的生物特性，或者增强尿激酶原和t—PA(人组织型纤溶酶原激活剂)的活性。
The purified t-PA has a higher affinity for fibrin than urokinase. In addition, the melanoma plasminogen activator appeared to be immunologically different from urokinase.
纯化的t-PA与尿激酶相比较，发现前者有更高亲和纤维蛋白的能力。
The purified t-PA has a higher affinity for fibrin than urokinase. In addition, the melanoma plasminogen activator appeared to be immunologically different from urokinase.
纯化的t-PA与尿激酶相比较，发现前者有更高亲和纤维蛋白的能力。
应用推荐